← FDA DRUG APPROVALS

FDA NDA · NDA020864

MAXALT

rizatriptan benzoate

Sponsor: ORGANON LLC

APPLICATION
NDA020864
TYPE
NDA
ORIGINAL APPROVAL
1998-06-29
LATEST ACTION
2019-10-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription, Discontinued

Products

MAXALT · ReferencePrescription
RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET · ORAL
MAXALT · ReferenceDiscontinued
RIZATRIPTAN BENZOATE EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2019-10-01Labeling · Supplement 23 · standard — Label ↗AP
2015-06-15Manufacturing (CMC) · Supplement 21 · standardAP
2014-05-29Manufacturing (CMC) · Supplement 20 · standardAP
2011-12-16Labeling · Supplement 11 · standard — Letter ↗AP
2011-12-16Efficacy · Supplement 18 · priority — Label ↗AP
2011-12-16Labeling · Supplement 16 · standard — Letter ↗AP
2011-12-16Labeling · Supplement 19 · standard — Letter ↗AP
2011-12-16Labeling · Supplement 17 · standard — Label ↗AP
2010-08-12Labeling · Supplement 13 · standard — Label ↗AP
2002-04-22Labeling · Supplement 8 · standard — Review ↗AP
2001-12-06Manufacturing (CMC) · Supplement 9 · standardAP
2001-01-25Manufacturing (CMC) · Supplement 6 · standardAP
2000-12-11Labeling · Supplement 7 · standard — Review ↗AP
2000-12-11Efficacy · Supplement 5 · standard — Review ↗AP
2000-12-11Labeling · Supplement 4 · standard — Review ↗AP
2000-06-21Efficacy · Supplement 2 · standard — Review ↗AP
1999-11-16Efficacy · Supplement 3 · standard — Letter ↗AP
1998-06-29Type 1 - New Molecular Entity · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →